Yao JC, Hassan M, Phan A, et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26(18):3063–72. https://doi.org/10.1200/JCO.2007.15.4377.

Article  PubMed  Google Scholar 

Dasari A, Shen C, Halperin D, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3(10):1335–42. https://doi.org/10.1001/JAMAONCOL.2017.0589.

Article  PubMed  PubMed Central  Google Scholar 

Mazzaferro V, Regalia E, Doci R, et al. Liver Transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334(11):693–700. https://doi.org/10.1056/NEJM199603143341104.

Article  CAS  PubMed  Google Scholar 

Mazzaferro V, Citterio D, Bhoori S, et al. Liver transplantation in hepatocellular carcinoma after tumour downstaging (XXL): a randomised, controlled, phase 2b/3 trial. Lancet Oncol. 2020;21(7):947–56. https://doi.org/10.1016/S1470-2045(20)30224-2.

Article  CAS  PubMed  Google Scholar 

Sapisochin G, Bruix J. Liver transplantation for hepatocellular carcinoma: outcomes and novel surgical approaches. Nat Rev Gastroenterol Hepatol. 2017;14(4):203–17. https://doi.org/10.1038/nrgastro.2016.193.

Article  PubMed  Google Scholar 

Durand F, Antoine C, Soubrane O. Liver transplantation in France. Liver Transpl. 2019;25(5):763–70. https://doi.org/10.1002/lt.25419.

Article  PubMed  Google Scholar 

Zarrinpar A, Busuttil RW. Liver transplantation: past, present and future. Nat Rev Gastroenterol Hepatol. 2013;10(7):434–40. https://doi.org/10.1038/nrgastro.2013.88.

Article  CAS  PubMed  Google Scholar 

Kwong AJ, Kim WR, Lake JR, et al. OPTN/SRTR 2019 annual data report: liver. Am J Transplant. 2021;21 Suppl 2(S2):208–315. https://doi.org/10.1111/AJT.16494.

Article  CAS  PubMed  Google Scholar 

Adam R, Karam V, Delvart V, et al. Evolution of indications and results of liver transplantation in Europe. A report from the European Liver Transplant Registry (ELTR). J Hepatol. 2012;57(3):675–88. https://doi.org/10.1016/J.JHEP.2012.04.015.

Article  PubMed  Google Scholar 

Austin MT, Leys CM, Feurer ID, et al. Liver transplantation for childhood hepatic malignancy: a review of the United Network for Organ Sharing (UNOS) database. J Pediatr Surg. 2006;41(1):182–6. https://doi.org/10.1016/J.JPEDSURG.2005.10.091.

Article  PubMed  Google Scholar 

Guiteau JJ, Cotton RT, Karpen SJ, O’Mahony CA, Goss JA. Pediatric liver transplantation for primary malignant liver tumors with a focus on hepatic epithelioid hemangioendothelioma: the UNOS experience. Pediatr Transplant. 2010;14(3):326–31. https://doi.org/10.1111/j.1399-3046.2009.01266.x.

Article  PubMed  Google Scholar 

Sapisochin G, Ivanics T, Heimbach J. Liver transplantation for intrahepatic cholangiocarcinoma: ready for prime time? Hepatology. 2022;75(2):455–72. https://doi.org/10.1002/hep.32258.

Article  PubMed  Google Scholar 

Moris D, Tsilimigras DI, Chakedis J, et al. Liver transplantation for unresectable colorectal liver metastases: a systematic review. J Surg Oncol. 2017;116(3):288–97. https://doi.org/10.1002/JSO.24671.

Article  PubMed  Google Scholar 

Mühlbacher F, Piza F. Orthotopic liver transplantation for secondary malignancies of the liver. Transplant Proc. 1987;19(1 Pt 3):2396–8.

PubMed  Google Scholar 

Hagness M, Foss A, Line PD, et al. Liver transplantation for nonresectable liver metastases from colorectal cancer. Ann Surg. 2013;257(5):800–6. https://doi.org/10.1097/SLA.0b013e3182823957.

Article  PubMed  Google Scholar 

Ruzzenente A, Bagante F, Bertuzzo F, et al. Liver resection for neuroendocrine tumor liver metastases within Milan criteria for liver transplantation. J Gastrointest Surg. 2019;23(1):93–100. https://doi.org/10.1007/s11605-018-3973-9. Multi-institutional retrospective study reporting survival outcomes and risk factors of patients with neuroendocrine liver metastases undergoing surgical resection.

le Treut YP, Grégoire E, Klempnauer J, et al. Liver transplantation for neuroendocrine tumors in Europe-results and trends in patient selection: a 213-case European liver transplant registry study. Ann Surg. 2013;257(5):807–15. https://doi.org/10.1097/SLA.0B013E31828EE17C.

Article  PubMed  Google Scholar 

Olausson M, Friman S, Herienius G, et al. Orthotopic liver or multivisceral transplantation as treatment of metastatic neuroendocrine tumors. Liver Transpl. 2007;13(3):327–33. https://doi.org/10.1002/LT.21056.

Article  PubMed  Google Scholar 

Frilling A, Malago M, Weber F, et al. Liver transplantation for patients with metastatic endocrine tumors: single-center experience with 15 patients. Liver Transpl. 2006;12(7):1089–96. https://doi.org/10.1002/LT.20755.

Article  PubMed  Google Scholar 

Rosenau J, Bahr MJ, von Wasielewski R, et al. Ki67, e-cadherin, and p53 as prognostic indicators of long-term outcome after liver transplantation for metastatic neuroendocrine tumors. Transplantation. 2002;73(3):386–94. https://doi.org/10.1097/00007890-200202150-00012.

Article  CAS  PubMed  Google Scholar 

le Treut YP, Grégoire E, Belghiti J, et al. Predictors of long-term survival after liver transplantation for metastatic endocrine tumors: an 85-case French multicentric report. Am J Transplant. 2008;8(6):1205–13. https://doi.org/10.1111/j.1600-6143.2008.02233.x.

Article  PubMed  Google Scholar 

Ruf J, Heuck F, Schiefer J, et al. Impact of multiphase 68Ga-DOTATOC-PET/CT on therapy management in patients with neuroendocrine tumors. Neuroendocrinology. 2010;91(1):101–9. https://doi.org/10.1159/000265561.

Article  CAS  PubMed  Google Scholar 

Mazzaferro V, Pulvirenti A, Coppa J. Neuroendocrine tumors metastatic to the liver: how to select patients for liver transplantation? J Hepatol. 2007;47(4):460–6. https://doi.org/10.1016/J.JHEP.2007.07.004.

Article  PubMed  Google Scholar 

Gedaly R, Daily MF, Davenport D, et al. Liver transplantation for the treatment of liver metastases from neuroendocrine tumors: an analysis of the UNOS database. Arch Surg. 2011;146(8):953–8. https://doi.org/10.1001/archsurg.2011.186.

Article  PubMed  Google Scholar 

Mazzaferro V, Sposito C, Coppa J, et al. The long-term benefit of liver transplantation for hepatic metastases from neuroendocrine tumors. Am J Transplant. 2016;16(10):2892–902. https://doi.org/10.1111/AJT.13831.

Article  CAS  PubMed  Google Scholar 

Touzios JG, Kiely JM, Pitt SC, et al. Neuroendocrine hepatic metastases: does aggressive management improve survival? Ann Surg. 2005;241(5):776–85. https://doi.org/10.1097/01.sla.0000161981.58631.ab.

Article  PubMed  PubMed Central  Google Scholar 

Lang H, Oldhafer KJ, Weimann A, et al. Liver transplantation for metastatic neuroendocrine tumors. Ann Surg. 1997;225(4):347–54. https://doi.org/10.1097/00000658-199704000-00002.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Organ Procurement & Transplantation Network (OPTN). Guidance to liver transplant programs and the National Liver Review Board for: adult MELD exception review. Available at: https://optn.transplant.hrsa.gov/media/esdjnjok/20200804_nlrb_adult_other_guidance.pdf.

Pavel M, Öberg K, Falconi M, et al. Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(7):844–60. https://doi.org/10.1016/j.annonc.2020.03.304. Latest ESMO guidelines on neuroendocrine tumors.

Pavel M, O’Toole D, Costa F, et al. ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site. Neuroendocrinology. 2016;103(2):172–185. https://doi.org/10.1159/000443167.

NANETS. 2022 Edition NANETS GUIDELINES. https://nanets.net/images/guidelines/21513_NANETS_2022_Guidelines_Compendium.pdf. Accessed 27 Nov 2022. Latest NANETS guidelines on neuroendocrine tumors.

Tran CG, Sherman SK, Chandrasekharan C, Howe JR. Surgical management of neuroendocrine tumor liver metastases. Surg Oncol Clin N Am. 2021;30(1):39–55. https://doi.org/10.1016/J.SOC.2020.08.001. Comprehensive review of treatment options for neuroendocrine liver metastases.

Strosberg JR, Benson AB, Huynh L, et al. Clinical benefits of above-standard dose of octreotide LAR in patients with neuroendocrine tumors for control of carcinoid syndrome symptoms: a multicenter retrospective chart review study. Oncologist. 2014;19(9):930–6. https://doi.org/10.1634/THEONCOLOGIST.2014-0120.

Article  PubMed  PubMed Central  Google Scholar 

Mayo SC, de Jong MC, Pulitano C, et al. Surgical management of hepatic neuroendocrine tumor metastasis: results from an international multi-institutional analysis. Ann Surg Oncol. 2010;17(12):3129–36. https://doi.org/10.1245/S10434-010-1154-5.

Rinke A, Müller HH, Schade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol. 2009;27(28):4656–63. https://doi.org/10.1200/JCO.2009.22.8510.

Article  CAS  PubMed  Google Scholar 

Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011;364(6):514–23. https://doi.org/10.1056/NEJMOA1009290.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kaçmaz E, Heidsma CM, Besselink MGH, et al. Treatment of liver metastases from midgut neuroendocrine tumours: a systematic review and meta-analysis. J Clin Med. 2019;8(3). https://doi.org/10.3390/JCM8030403.

Spolverato G, Bagante F, Aldrighetti L, et al. Management and outcomes of patients with recurrent neuroendocrine liver metastasis after curative surgery: An international multiinstitutional analysis. J Surg Oncol. 2017;116(3):298–306. https://doi.org/10.1002/JSO.24670.

Kiritani S, Arita J, Matsumura M, et al. Repeat hepatectomy for patients with recurrentneuroendocrine liver metastasis: comparison with first hepatectomy. Surgery (UnitedStates). 2020;167(2):404–9. https://doi.org/10.1016/j.surg.2019.08.020. Retrospective analysis describing, indications, clinicopathological factors and outcomes of patients undergoing repeated hepatectomies for neuroendocrine metastases.

Elias D, Lefevre JH, Duvillard P, et al. Hepatic metastases from neuroendocrine tumors with a “thin slice” pathological examination: they are many more than you think. Ann Surg. 2010;251(2):307–10. https://doi.org/10.1097/SLA.0B013E3181BDF8CF.

Article  PubMed  Google Scholar 

Sarmiento JM, Heywood G, Rubin J, Ilstrup DM, Nagorney DM, Que FG. Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. J Am Coll Surg. 2003;197(1):29–37. https://doi.org/10.1016/S1072-7515(03)00230-8.

Article  PubMed  Google Scholar 

Glazer ES, Tseng JF, Al-Refaie W, et al. Long-term survival after surgical management of neuroendocrine hepatic metastases. HPB (Oxford). 2010;12(6):427–33. https://do